美洛西林钠舒巴坦钠治疗新生儿肺炎的疗效分析

Analysis of efficacy of mezlocillin sodium and sulbactam sodium in the treatment of neonatal pneumonia

目的 分析美洛西林钠舒巴坦钠治疗新生儿肺炎的疗效。方法 88例新生儿肺炎患儿,采用随机数字表法分为对照组和实验组,每组44例。对照组接受青霉素钠治疗,实验组接受美洛西林钠舒巴坦钠治疗。比较两组临床疗效,症状消失时间及住院时间,治疗前后血气指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))]水平、炎症指标[白细胞介素-6(IL-6)、降钙素原(PCT)、血沉(ESR)]水平,不良反应发生情况。结果 实验组临床总有效率97.73%高于对照组的81.82%,差异具有统计学意义(P<0.05)。实验组咳嗽、发热、肺部啰音消失时间及住院时间分别为(3.10±1.73)、(3.09±0.47)、(3.80±1.44)、(9.78±2.65)d,均短于对照组的(5.22±1.69)、(4.76±0.41)、(5.23±1.28)、(11.75±2.36)d,差异具有统计学意义(P<0.05)。治疗后,实验组PaO_(2)(70.08±6.74)mm Hg(1 mm Hg=0.133 kPa)高于对照组的(61.13±6.02)mm Hg,PaCO_(2)(42.13±5.71)mm Hg低于对照组的(45.88±5.26)mm Hg,差异具有统计学意义(P<0.05)。治疗后,实验组IL-6、PCT、ESR分别为(0.047±0.016)ng/L、(0.3±0.1)μg/L、(18±3)mm/h,均低于对照组的(0.054±0.010)ng/L、(0.5±0.1)μg/L、(20±4)mm/h,差异具有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论 美洛西林钠舒巴坦钠治疗新生儿肺炎的疗效显著,可促进血气指标、炎症免疫指标改善,且安全性高,值得临床推广应用。

Objective To analyze the efficacy of mezlocillin sodium and sulbactam sodium in the treatment of neonatal pneumonia.Methods A total of 88 cases of neonatal pneumonia were divided into control group and experimental group according to the random numerical table,with 44 cases in each group.The control group was treated with penicillin sodium,and the experimental group was treated with mezlocillin sodium and sulbactam sodium.Both groups were compared in terms of clinical efficacy,symptom disappearance time,hospital stay,blood gas indexes[arterial partial pressure of oxygen(PaO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2))]and inflammatory markers[interleukin-6(IL-6),procalcitonin(PCT),erythrocyte sedimentation rate(ESR)]before and after treatment,and the occurrence of adverse reactions.Results The total effective rate of the experimental group was 97.73%,which was higher than that of 81.82%of the control group,and the difference was statistically significant(P<0.05).The disappearance time of cough,fever,lung rales and hospital stay were(3.10±1.73),(3.09±0.47),(3.80±1.44)and(9.78±2.65)d in the experimental group,which were shorter than those of(5.22±1.69),(4.76±0.41),(5.23±1.28)and(11.75±2.36)d in the control group,and the differences were statistically significant(P<0.05).After treatment,PaO_(2) of(70.08±6.74)mm Hg(1 mm Hg=0.133 kPa)in the experimental group was higher than that of(61.13±6.02)mm Hg in the control group;PaCO_(2) of(42.13±5.71)mm Hg in the experimental group was lower than that of(45.88±5.26)mm Hg in the control group;the differences were statistically significant(P<0.05).After treatment,IL-6,PCT and ESR were(0.047±0.016)ng/L,(0.3±0.1)μg/L and(18±3)mm/h in the experimental group,which were lower than those of(0.054±0.010)ng/L,(0.5±0.1)μg/L and(20±4)mm/h in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Mezlocillin sodium and sulbactam sodium is effective in the treatment of neonatal pneumonia,which can promote the improvement of blood gas indexes and immune inflammation indicators with high safety,and is worthy of clinical promotion.